GlassScriptPhysician profile
Christopher Bankhead
NPI 1467871723
$9,288.01
in general payments reported to CMS, 2019-2025
9 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,347 · 2021: $2,434 · 2022: $87.59 · 2023: $2,590 · 2024: $1,680 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,617 · Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,617.17 |
| Food and Beverage | $1,802.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,245.28 | 2020-2024 | |
| Alon Medical Technology | $3,152.88 | 2020-2024 | |
| Encore Medical, LP | $1,304.06 | 2023 | Djo Surgical |
| Stryker Corporation | $365.77 | 2021-2025 | Samurai, Citrefix, Blueprint Patient Specific Instrumentation |
| Smith+Nephew, INC. | $102.68 | 2022-2025 | Bone Anchors With Arthroscopic Delivery System |
| Siemens Medical Solutions USA, INC. | $66.26 | 2024 | Acuson Sequoia Diagnostic Ultrasound System, Acuson Freestyle Diagnostic Ultrasound System, Acuson Origin Diagnostic Ultrasound System |
| Bioventus LLC | $19.54 | 2025 | Durolane |
| Pacira Pharmaceuticals Incorporated | $16.57 | 2024 | Iovera, Exparel |
| Linvatec Corporation | $14.97 | 2025 | Biobrace 23mm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bankhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.